BioCentury
ARTICLE | Company News

arGEN-X, Leo Pharma deal

June 22, 2015 7:00 AM UTC

arGEN-X granted Leo exclusive, worldwide rights to develop and commercialize ARGX-112, a preclinical antibody to treat inflammation-related skin diseases. arGEN-X will receive EUR4.5 million ($5 mill...